These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 21963632)

  • 1. A novel series of (S)-2,7-substituted-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor α/γ dual agonists with protein-tyrosine phosphatase 1B inhibitory activity.
    Otake K; Azukizawa S; Fukui M; Shibabayashi M; Kamemoto H; Miike T; Kunishiro K; Kasai M; Shirahase H
    Chem Pharm Bull (Tokyo); 2011; 59(10):1233-42. PubMed ID: 21963632
    [TBL] [Abstract][Full Text] [Related]  

  • 2. 2-Acyl-tetrahydroisoquinoline-3-carboxylic acids: lead compounds with triple actions, peroxisome proliferator-activated receptor α/γ agonist and protein-tyrosine phosphatase 1B inhibitory activities.
    Otake K; Azukizawa S; Takahashi K; Fukui M; Shibabayashi M; Kamemoto H; Kasai M; Shirahase H
    Chem Pharm Bull (Tokyo); 2011; 59(7):876-9. PubMed ID: 21720040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel 2,7-Substituted (S)-1,2,3,4-Tetrahydroisoquinoline-3-carboxylic Acids: Peroxisome Proliferator-Activated Receptor γ Partial Agonists with Protein-Tyrosine Phosphatase 1B Inhibition.
    Otake K; Azukizawa S; Takeda S; Fukui M; Kawahara A; Kitao T; Shirahase H
    Chem Pharm Bull (Tokyo); 2015; 63(12):998-1014. PubMed ID: 26633022
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: peroxisome proliferator-activated receptor γ selective agonists with protein-tyrosine phosphatase 1B inhibition.
    Otake K; Azukizawa S; Fukui M; Kunishiro K; Kamemoto H; Kanda M; Miike T; Kasai M; Shirahase H
    Bioorg Med Chem; 2012 Jan; 20(2):1060-75. PubMed ID: 22197396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 2-Acyl-3-carboxyl-tetrahydroisoquinoline Derivatives: Mixed-Type PTP1B Inhibitors without PPARγ Activation.
    Morishita K; Shoji Y; Fukui M; Ito Y; Kitao T; Ozawa SI; Hirono S; Shirahase H
    Chem Pharm Bull (Tokyo); 2018; 66(12):1131-1152. PubMed ID: 30504630
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Insulin sensitization by a novel partial peroxisome proliferator-activated receptor γ agonist with protein tyrosine phosphatase 1B inhibitory activity in experimental osteoporotic rats.
    Kubo M; Fukui M; Ito Y; Kitao T; Shirahase H; Hinoi E; Yoneda Y
    J Pharmacol Sci; 2014; 124(2):276-85. PubMed ID: 24553405
    [TBL] [Abstract][Full Text] [Related]  

  • 7. (S)-1,2,3,4-Tetrahydroisoquinoline Derivatives Substituted with an Acidic Group at the 6-Position as a Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonist.
    Morishita K; Miike T; Takeda S; Fukui M; Ito Y; Kitao T; Ozawa SI; Hirono S; Shirahase H
    Chem Pharm Bull (Tokyo); 2019; 67(11):1211-1224. PubMed ID: 31685749
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Synthesis and biological evaluation of (S)-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acids: a novel series of PPAR gamma agonists.
    Azukizawa S; Kasai M; Takahashi K; Miike T; Kunishiro K; Kanda M; Mukai C; Shirahase H
    Chem Pharm Bull (Tokyo); 2008 Mar; 56(3):335-45. PubMed ID: 18310946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Design, synthesis, and PPARalpha/gamma agonistic activity of novel tetrahydroisoquinoline derivatives].
    Yu R; Zhou YL; Huan Y; Liu Q; Shen ZF; Liu ZZ
    Yao Xue Xue Bao; 2011 Mar; 46(3):311-6. PubMed ID: 21626786
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and Evaluation of a Novel Series of 2,7-Substituted-6-tetrazolyl-1,2,3,4-tetrahydroisoquinoline Derivatives as Selective Peroxisome Proliferator-Activated Receptor γ Partial Agonists.
    Morishita K; Ito Y; Otake K; Takahashi K; Yamamoto M; Kitao T; Ozawa SI; Hirono S; Shirahase H
    Chem Pharm Bull (Tokyo); 2021; 69(4):333-351. PubMed ID: 33790079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tetrahydroisoquinoline PPARgamma agonists: design of novel, highly selective non-TZD antihyperglycemic agents.
    Henry JR; Li Y; Warshawsky AM; Brozinick JT; Hawkins ED; Misener EA; Briere DA; Montrose-Rafizadeh C; Zink RW; Yumibe NP; Ajamie RT; Wilken B; Devanarayan V
    Bioorg Med Chem Lett; 2006 Dec; 16(24):6293-7. PubMed ID: 17005393
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PAR-1622 is a selective peroxisome proliferator-activated receptor gamma partial activator with preserved antidiabetic efficacy and broader safety profile for fluid retention.
    Kim MK; Chae YN; Kim HS; Choi SH; Son MH; Kim SH; Kim JK; Moon HS; Park SK; Shin YA; Kim JG; Lee CH; Lim JI; Shin CY
    Arch Pharm Res; 2009 May; 32(5):721-7. PubMed ID: 19471887
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Design, synthesis, and structure-activity relationship studies of novel 2,4,6-trisubstituted-5-pyrimidinecarboxylic acids as peroxisome proliferator-activated receptor gamma (PPARgamma) partial agonists with comparable antidiabetic efficacy to rosiglitazone.
    Seto S; Okada K; Kiyota K; Isogai S; Iwago M; Shinozaki T; Kitamura Y; Kohno Y; Murakami K
    J Med Chem; 2010 Jul; 53(13):5012-24. PubMed ID: 20527969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two thiophenes compounds are partial peroxisome proliferator-activated receptor α/γ dual agonists.
    Zheng Z; Yang Y; Shao H; Liu Z; Lu X; Xu Y; He X; Jiang W; Jiang Q; Zhao B; Zhang H; Li Z; Si S
    Biol Pharm Bull; 2011; 34(10):1631-4. PubMed ID: 21963508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Design, synthesis and antidiabetic activity of novel tetrahydrocarboline PPAR regulators].
    Peng K; Huan Y; Liu Q; Shen ZF; Liu ZZ
    Yao Xue Xue Bao; 2014 Apr; 49(4):490-6. PubMed ID: 24974466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.
    Tsuchida A; Yamauchi T; Takekawa S; Hada Y; Ito Y; Maki T; Kadowaki T
    Diabetes; 2005 Dec; 54(12):3358-70. PubMed ID: 16306350
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and evaluation of 2-Nonylaminopyridine derivatives as PPAR ligands.
    Usui S; Fujieda H; Suzuki T; Yoshida N; Nakagawa H; Ogura M; Makishima M; Miyata N
    Chem Pharm Bull (Tokyo); 2007 Jul; 55(7):1053-9. PubMed ID: 17603200
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinnamic acid based thiazolidinediones inhibit human P450c17 and 3beta-hydroxysteroid dehydrogenase and improve insulin sensitivity independent of PPARgamma agonist activity.
    Arlt W; Neogi P; Gross C; Miller WL
    J Mol Endocrinol; 2004 Apr; 32(2):425-36. PubMed ID: 15072549
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of YM440 a hypoglycemic agent on binding to a peroxisome proliferator-activated receptor gamma and its transactivation.
    Kurosaki E; Nakano R; Shimaya A; Yoshida S; Ida M; Suzuki T; Shibasaki M; Shikama H
    Biochem Pharmacol; 2003 Mar; 65(5):795-805. PubMed ID: 12628477
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
    Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
    Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.